CRDL – cardiol therapeutics inc. - class a common shares (US:NASDAQ)
Stock Stats
News
Cardiol Therapeutics (NASDAQ:CRDL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 [Yahoo! Finance]
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 [Yahoo! Finance]
Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Form 6-K Cardiol Therapeutics For: Dec 01
Form 6-K Cardiol Therapeutics For: Nov 13
Form SUPPL Cardiol Therapeutics
Form F-X Cardiol Therapeutics Filed by: Cardiol Therapeutics Inc.
Form F-10 Cardiol Therapeutics
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.